Indication Covered

The report covers Dry Age-Related Macular Degeneration (Dry AMD) as a chronic, progressive, degenerative retinal disease, with emphasis on its clinical burden, treatment patterns, therapeutic innovation, and commercial market development across the seven major markets. Dry AMD is primarily characterized by progressive deterioration of the retinal pigment epithelium (RPE), accumulation of drusen beneath the retina, and gradual damage to photoreceptor cells within the macula. The condition can range from early-stage disease with limited retinal changes and minimal visual impairment to advanced disease characterized by geographic atrophy (GA), irreversible retinal tissue loss, and substantial central vision impairment, requiring nutritional supplementation, supportive management, intravitreal therapies, and emerging advanced treatment approaches.

The indication scope includes major clinical manifestations and associated disease conditions relevant to treatment demand, including:

  • Early Dry Age-Related Macular Degeneration
  • Intermediate Dry Age-Related Macular Degeneration
  • Advanced Dry Age-Related Macular Degeneration
  • Geographic Atrophy (GA)
  • Non-central Geographic Atrophy
  • Central Geographic Atrophy

Intermediate Dry AMD remains the primary focus because of its substantial patient population, risk of progression to advanced disease, and increasing requirement for disease-monitoring and preventive treatment strategies. The report also considers Geographic Atrophy because of its significant clinical burden, irreversible vision loss, and emerging commercial opportunity following the introduction of complement-inhibiting therapies. Other difficult-to-treat manifestations and advanced forms, including foveal-involving geographic atrophy, bilateral retinal degeneration, and progressive central vision impairment, are evaluated as areas of continuing clinical need.

The treatment landscape covers nutritional supplementation, antioxidant therapies, complement inhibitors, supportive and low-vision management, and emerging gene and cell-based therapies. Particular attention is given to advanced therapies targeting complement C3, complement C5, retinal inflammation, oxidative stress, and retinal pigment epithelium degeneration, as well as emerging gene therapy, regenerative medicine, and next-generation retinal protection approaches.

Epidemiology Parameters

Dry AMD represents a significant chronic and progressive disease burden across the major healthcare markets covered in the report. Epidemiological patterns vary substantially between countries because of differences in genetic susceptibility, aging populations, environmental factors, smoking prevalence, healthcare access, disease awareness, diagnostic practices, and availability of ophthalmologists, retinal specialists, and advanced retinal imaging services.

The epidemiology assessment provides a structured evaluation of the Dry AMD population from overall prevalence through diagnosis and treatment. Key parameters include:

  • Total Dry AMD patient population
  • Prevalent population
  • Incidence population, where reliable data are available
  • Diagnosed patient population
  • Treated patient population
  • Untreated patient population
  • Treatment-eligible population
  • Disease severity distribution
  • Early Dry AMD population
  • Intermediate Dry AMD population
  • Advanced Dry AMD population
  • Geographic Atrophy population
  • Non-central Geographic Atrophy population
  • Central Geographic Atrophy population
  • Age distribution
  • Gender distribution, where available
  • Diagnosis rate
  • Treatment rate
  • Treatment penetration
  • Regional disease burden
  • Epidemiological trends

The analysis distinguishes between the broader prevalent population and patients who are diagnosed and actively receiving treatment. This distinction is particularly important because a considerable proportion of patients may remain undiagnosed, particularly during early disease stages, or may receive only routine monitoring and nutritional supplementation without requiring advanced pharmaceutical intervention.

The report also evaluates the increasing recognition of Dry AMD as a progressive retinal degenerative disease associated with aging and multiple biological mechanisms. Associated manifestations such as geographic atrophy, central vision loss, impaired reading ability, reduced mobility, and increased dependence on caregivers can influence treatment decisions, disease monitoring, healthcare utilization, and long-term management strategies.

Patient Segmentation

The Dry AMD patient population is segmented according to disease severity, disease manifestation, treatment status, and therapeutic requirements. This approach provides a clearer understanding of the population eligible for different treatment categories and helps assess the potential addressable population for advanced therapies.

By Disease Severity

Mild: Patients with early-stage disease and limited drusen accumulation are generally managed through regular ophthalmic monitoring, lifestyle modifications, smoking cessation, and nutritional counseling. Treatment decisions are influenced by retinal changes, visual function, family history, previous disease progression, and patient-specific risk factors.

Moderate: Patients with intermediate Dry AMD and more extensive drusen accumulation or pigmentary abnormalities may require AREDS2-based nutritional supplementation and regular retinal imaging. Increasing treatment expectations and concerns regarding progression toward geographic atrophy can encourage closer monitoring and consideration of emerging retinal-protective therapies.

Severe: Patients with advanced Dry AMD, substantial retinal pigment epithelium degeneration, geographic atrophy, or significant central vision impairment are more likely to require advanced intravitreal therapies, low-vision rehabilitation, and supportive management. This segment represents a major contributor to advanced Dry AMD treatment demand.

By Disease Type

  • Early Dry AMD
  • Intermediate Dry AMD
  • Advanced Dry AMD
  • Geographic Atrophy
  • Non-central Geographic Atrophy
  • Central Geographic Atrophy

By Treatment Status

  • Diagnosed and Treated
  • Diagnosed and Untreated
  • Undiagnosed

The treatment-status segmentation helps identify the gap between the total disease population and the population actively participating in healthcare treatment. Improvements in awareness, routine ophthalmic screening, retinal imaging capabilities, specialist availability, and healthcare access can gradually increase the diagnosed and treated population.

By Treatment Requirement

  • Nutritional Supplementation Candidates
  • Antioxidant Therapy Candidates
  • Intravitreal Complement Inhibitor Candidates
  • Advanced Geographic Atrophy Therapy Candidates
  • Gene Therapy Candidates
  • Cell-Based and Regenerative Therapy Candidates

This segmentation helps evaluate how changes in treatment guidelines, physician preferences, reimbursement, and therapy availability can shift patients between conventional disease-management approaches and advanced pharmaceutical treatment categories.

Geographic Coverage

The report provides detailed market, epidemiology, treatment, and competitive analysis across 7 major markets:

  1. United States
  2. China
  3. Japan
  4. Germany
  5. United Kingdom
  6. France
  7. India

The geographic analysis considers differences in patient population, diagnosis rates, healthcare infrastructure, treatment accessibility, reimbursement, therapeutic penetration, regulatory environment, physician adoption, and competitive activity. These factors are particularly important because the commercial opportunity for Dry AMD therapies differs considerably between mature pharmaceutical markets and high-growth emerging markets.

United States

The United States represents one of the most important Dry AMD markets, supported by high disease awareness, established ophthalmology and retinal specialist networks, strong pharmaceutical innovation, and early availability of advanced geographic atrophy therapies. Pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) have established an important commercial treatment category among eligible patients with geographic atrophy.

The market is also characterized by significant competition between nutritional supplementation, established supportive management, and newer complement-inhibiting treatments. Treatment selection is influenced by clinical efficacy, safety, injection frequency, risk of ocular adverse events, payer restrictions, patient preference, and previous treatment history. Continued development of gene therapies, cell-based therapies, and next-generation complement inhibitors is expected to further intensify competition.

China

China represents a significant long-term growth opportunity because of its large aging population and increasing recognition of Dry AMD as a progressive retinal disease requiring sustained monitoring and management. Improvements in healthcare infrastructure, ophthalmic diagnostic capabilities, and specialist availability are supporting greater diagnosis and treatment access.

The market is gradually experiencing increased demand for advanced retinal therapies, although affordability, reimbursement coverage, treatment accessibility, and differences between urban and rural healthcare services remain important considerations. Expansion of domestic pharmaceutical development, innovative ophthalmic drug research, and greater availability of cost-effective treatment options may also increase competitive intensity.

Japan

Japan represents a mature healthcare and pharmaceutical market with sophisticated ophthalmic infrastructure and established retinal specialist services. Its aging population and increasing awareness of age-related retinal degeneration support continued demand for advanced Dry AMD management.

Treatment decisions are influenced by clinical efficacy, safety, reimbursement conditions, dosing convenience, and physician familiarity. The market also provides opportunities for innovative therapies that can demonstrate meaningful improvements in geographic atrophy progression, visual function preservation, treatment durability, or administration convenience.

Germany

Germany represents a leading European Dry AMD market with established ophthalmology networks and strong utilization of advanced retinal diagnostic and treatment services. Treatment pathways are supported by a developed healthcare system, specialist retinal clinics, and established clinical management practices.

The market is increasingly influenced by healthcare reimbursement considerations, treatment optimization, and the introduction of therapies with differentiated mechanisms. Continued adoption of nutritional supplementation, advanced geographic atrophy treatments, and emerging retinal-protective therapies is expected to remain important to market development.

United Kingdom

The UK Dry AMD market benefits from established clinical guidelines, ophthalmology services, and structured retinal disease-monitoring pathways. Nutritional supplementation and regular retinal monitoring remain important components of disease management, while advanced therapies are attracting increasing attention for patients with geographic atrophy.

Market development is influenced by healthcare-system treatment criteria, cost-effectiveness considerations, clinical outcomes, and access to specialist retinal services. Increasing emphasis on preserving visual function, improving quality of life, and delaying progression toward advanced disease supports continued innovation in targeted retinal treatment.

France

France represents an important European market supported by developed healthcare infrastructure, specialist ophthalmology services, and established reimbursement mechanisms. Nutritional supplementation and regular monitoring remain important treatment approaches, while emerging complement inhibitors provide additional treatment opportunities for patients with geographic atrophy.

Market growth is influenced by therapeutic innovation, treatment accessibility, reimbursement conditions, and increasing use of advanced retinal therapies. The introduction of newer mechanisms, regenerative treatments, and potential gene-based approaches is expected to shape the competitive environment.

India

India represents a high-potential Dry AMD market because of its large and aging population, expanding healthcare infrastructure, increasing disease awareness, and improving access to ophthalmic specialty care. Diagnosis and treatment rates have significant potential for expansion as healthcare services, retinal imaging facilities, and specialist networks become more accessible.

Affordability remains an important factor influencing treatment selection, particularly for advanced intravitreal biologic and specialty therapies. Greater availability of cost-effective nutritional supplements, improved ophthalmic screening, increasing specialist coverage, and improving patient awareness can support future market expansion.

Market Segmentation

The Dry AMD market is segmented across drug class, treatment type, route of administration, patient age group, and distribution channel. The segmentation captures both established disease-management categories and emerging therapeutic approaches, including advanced pharmaceutical interventions for geographic atrophy.

By Drug Class

Complement Inhibitors
Complement inhibitors represent a major segment of the advanced Dry AMD market because of their targeted mechanism and established role in geographic atrophy treatment. These therapies selectively interfere with components of the complement cascade involved in retinal inflammation, cellular damage, and progression of geographic atrophy.

The complement inhibitor segment includes C3 inhibitors and C5 inhibitors. Pegcetacoplan (Syfovre), which targets complement C3, and avacincaptad pegol (Izervay), which targets complement C5, represent the principal commercially approved therapies in the United States. Increasing physician familiarity, clinical evidence, and treatment experience continue to support the development of this therapeutic category.

Antioxidants and Nutritional Supplements
Antioxidants and nutritional supplements represent an important segment because of their established role in reducing the risk of progression among patients with intermediate Dry AMD. AREDS2-based formulations containing lutein, zeaxanthin, vitamin C, vitamin E, zinc, and copper are widely used in appropriate patient populations.

The segment includes antioxidant formulations, carotenoid-based supplements, and mineral-based nutritional combinations. Continued awareness of preventive treatment strategies and increasing ophthalmic screening are expected to support demand for these products.

Emerging Targeted and Regenerative Therapies
Emerging targeted and regenerative therapies represent an evolving segment because of growing demand for treatments capable of addressing retinal degeneration and preserving visual function. These approaches include gene therapies, neuroprotective agents, retinal pigment epithelium replacement therapies, and other investigational treatments.

Continued pipeline development and clinical differentiation could increase the role of these therapies in patients with advanced geographic atrophy and those who experience progressive retinal degeneration despite conventional management.

By Treatment Type

  • Nutritional Supplementation
  • Antioxidant Therapy
  • Complement C3 Inhibitors
  • Complement C5 Inhibitors
  • Supportive and Low-Vision Management
  • Emerging Gene and Cell-Based Therapies

Complement inhibitors are increasingly important because of their ability to slow geographic atrophy lesion growth. Nutritional supplementation maintains market relevance because of its established role in intermediate Dry AMD, while emerging gene and cell-based treatments represent potential future treatment opportunities.

By Route of Administration

  • Oral
  • Intravitreal Injection
  • Topical
  • Subcutaneous
  • Other Routes

Oral administration remains important within nutritional supplementation and antioxidant treatment, while intravitreal administration is the principal route for currently approved complement inhibitors targeting geographic atrophy. Other routes remain relevant primarily within investigational drug development and emerging retinal-protection approaches.

By Patient Age Group

  • Below 50 Years
  • 50–59 Years
  • 60–69 Years
  • 70–79 Years
  • 80 Years and Above

Patients aged 60–79 years represent an important treatment population because of the increasing prevalence of age-related retinal degeneration with advancing age. The population aged 80 years and above represents an important adjacent treatment segment because of its higher likelihood of advanced retinal changes, geographic atrophy, and visual impairment.

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Distribution patterns vary by treatment type, country, reimbursement environment, and healthcare system. Specialty pharmacies and hospital-based dispensing channels are particularly relevant for high-cost intravitreal and specialty therapies, while retail and online pharmacies have greater relevance for nutritional supplements and conventional supportive treatments.

Market Dynamics

Growth Drivers

Increasing Adoption of Advanced Geographic Atrophy Therapies
Advanced therapies continue to be one of the strongest growth drivers in the Dry AMD market. Their ability to selectively interfere with key complement pathways has introduced pharmaceutical treatment options for patients with geographic atrophy, a previously underserved advanced manifestation of the disease.

The growing use of pegcetacoplan and avacincaptad pegol is particularly important as physicians increasingly consider disease progression, treatment durability, safety, injection frequency, and potential visual-function benefits when selecting therapies. Expanded clinical experience and improved physician familiarity are also supporting adoption.

Advancement in Retinal Disease Biology-Based Drug Development
Advances in understanding the biological mechanisms underlying Dry AMD have created opportunities for more precise therapeutic intervention. Pharmaceutical companies are increasingly investing in therapies designed to selectively target complement activation, oxidative stress, retinal inflammation, photoreceptor degeneration, and retinal pigment epithelium dysfunction rather than relying solely on supportive treatment approaches.

Development activity is focused on novel complement pathways, gene therapies, retinal cell replacement, neuroprotective agents, improved treatment durability, and potentially more personalized approaches to treatment selection. These developments are expected to increase therapeutic competition.

Increasing Healthcare Access in Emerging Markets
Improving healthcare infrastructure and rising healthcare expenditure are increasing access to ophthalmic diagnosis and treatment in emerging markets. Expansion of ophthalmology networks, availability of optical coherence tomography (OCT), and greater disease awareness are also helping identify patients who previously remained undiagnosed or untreated.

China and India are particularly important growth opportunities because of their large aging populations and substantial potential patient bases. Increased reimbursement, wider availability of advanced therapies, and development of cost-effective treatment options could accelerate market penetration.

Growing Recognition of Dry AMD-Related Visual Disability
The increasing understanding of Dry AMD as a progressive retinal degenerative disease is encouraging more comprehensive disease management. Recognition of geographic atrophy, central vision loss, impaired reading ability, and reduced independence can encourage earlier diagnosis, specialist management, and continued treatment monitoring.

This shift can increase treatment intensity and create demand for therapies capable of slowing retinal degeneration and preserving visual function over longer periods.

Market Restraints

High Cost of Advanced Therapies
Biologic and other targeted therapies often carry substantially higher treatment costs than conventional nutritional supplementation. Intravitreal complement inhibitors require repeated administration and specialist ophthalmic procedures, increasing the overall treatment burden for patients and healthcare systems.

In emerging markets, limited reimbursement coverage and high out-of-pocket expenditure can restrict access to advanced treatment. Cost considerations may therefore continue to influence treatment selection and delay the adoption of innovative therapies.

Treatment Accessibility Gap
Unequal access to ophthalmologists, retinal specialists, specialty clinics, diagnostic imaging services, and advanced medicines remains a major challenge. Rural and underserved populations may experience longer diagnostic delays and fewer treatment options.

Differences in healthcare infrastructure between regions can therefore result in significant variations in diagnosis, treatment penetration, and disease outcomes. Limited availability of advanced retinal imaging can also affect the identification and monitoring of early and intermediate Dry AMD.

Variable Patient Response and Treatment Limitations
Although advanced therapies have introduced new treatment opportunities for geographic atrophy, treatment response is not uniform across patients. Complement inhibitors primarily slow the rate of lesion enlargement rather than reverse existing retinal damage or restore lost vision.

Some individuals may experience inadequate treatment benefit, ocular adverse events, treatment intolerance, or discontinuation because of repeated injection requirements. The need for long-term monitoring and continued treatment creates additional challenges and continuing demand for therapies offering improved safety, durability, and preservation of visual function.

Competitive Landscape

The global Dry AMD market is characterized by increasing competition among pharmaceutical companies with established ophthalmology portfolios and emerging developers focused on differentiated mechanisms and treatment approaches.

Leading companies covered in the competitive assessment include:

  • Apellis Pharmaceuticals
  • Astellas Pharma
  • Iveric Bio
  • Roche
  • Genentech
  • Annexon Biosciences
  • Ocugen
  • Lineage Cell Therapeutics
  • Alkeus Pharmaceuticals
  • Belite Bio

Competition is increasingly focused on demonstrating superior or differentiated clinical outcomes rather than simply introducing additional therapies within existing drug classes. Companies are investing in novel complement mechanisms, gene therapy, retinal cell replacement, improved dosing schedules, treatment durability, safety profiles, and preservation of visual function.

The competitive environment is also being influenced by treatment costs, reimbursement restrictions, physician familiarity with established products, and the clinical differentiation of emerging therapies. Complement C3 inhibitors, C5 inhibitors, gene therapies, and other regenerative approaches are expected to remain important areas of competition.

Pipeline innovation is another major competitive factor. Companies with strong clinical-development capabilities and diversified ophthalmology portfolios may be better positioned to respond to changing treatment preferences and emerging unmet needs. The development of potentially longer-lasting or one-time treatments could also create competitive differentiation against currently available therapies requiring repeated intravitreal administration.

Recent Developments

  • September 2026 – Ocugen advances OCU410 Phase 3 gene therapy development: Ocugen announced the first patient dosing in the global Phase 3 ArMaDa3 registrational trial evaluating OCU410 (AAV5-hRORA), an investigational modifier gene therapy for geographic atrophy secondary to Dry AMD. The program received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in July 2026 and is designed as a potentially one-time subretinal treatment targeting multiple disease pathways. The development highlights increasing industry interest in gene-based retinal therapies and their potential to reduce dependence on repeated intravitreal injections.
  • August 2026 – Annexon expands vonaprument Phase 3 clinical development program: Annexon announced the expansion of its Phase 3 ARCHER II clinical program evaluating vonaprument for geographic atrophy secondary to Dry AMD. The company added a Month 24 dual primary endpoint alongside the existing Month 15 primary endpoint and initiated an open-label extension study. The program reflects continued investment in complement-based immunotherapies designed to preserve visual function, address progressive retinal degeneration, and improve clinical outcomes in patients with geographic atrophy.

Report Coverage

The report provides comprehensive assessment of the Dry Age-Related Macular Degeneration market across the seven specified major markets. It integrates epidemiological analysis with commercial market assessment to provide a broader understanding of the current and future treatment landscape.

The study covers:

  • Indication Covered
  • Epidemiology Parameters
  • Patient Segmentation
  • Geographic Coverage
  • Market Segmentation
  • Units of Measurement
  • Study Period
  • Data Sources
  • Companies Covered
  • Report Deliverables
  • Out of Scope
  • Customization